If the judge revokes the FDA’s authorization of mifepristone, lawyers believe that would be unprecedented. “We are not aware of any case in which a court has removed a drug from the market over FDA’s objection,” a group of food and drug law scholars wrote in an amicus brief for the FDA.
Read more at the LA Times